Wang Qinwen, Walsh Dominic M, Rowan Michael J, Selkoe Dennis J, Anwyl Roger
Department of Physiology and Pharmacology, Trinity College, Dublin 2, Ireland.
J Neurosci. 2004 Mar 31;24(13):3370-8. doi: 10.1523/JNEUROSCI.1633-03.2004.
The mechanisms of action of human synthetic and naturally secreted cell-derived amyloid beta-peptide (Abeta)(1-42) on the induction of long-term potentiation (LTP) were investigated in the medial perforant path to dentate granule cell synapses in hippocampal slices. Synthetic and cell-derived Abeta strongly inhibited high-frequency stimulation (HFS)-induced LTP at peak HFS and 1 hr after HFS. Cell-derived Abeta was much more potent than synthetic Abeta at inhibiting LTP induction, with threshold concentrations of approximately 1 and 100-200 nm, respectively. The involvement of various kinases in Abeta-mediated inhibition of LTP induction was investigated by applying Abeta in the presence of inhibitors of these kinases. The c-Jun N-terminal kinase (JNK) inhibitor JNKI prevented the block of LTP induction by both synthetic and cell-derived Abeta. The block of LTP induced by synthetic Abeta was also prevented by the JNK inhibitor anthra[1,9-cd]pyrazol-6(2H)-one, the cyclin-dependent kinase 5 (Cdk5) inhibitors butyrolactone and roscovitine, and the p38 MAP kinase (MAPK) inhibitor 4-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)-5-(4-pyridyl)-1H-imidazole but not by the p42-p44 MAP kinase inhibitor 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene. The group I-group II metabotropic glutamate receptor (mGluR) antagonist 2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid and the mGluR5 antagonist methyl-6-(phenylethynyl)pyridine prevented the block of LTP induction by Abeta. However, thealpha7 nicotinic ACh receptor antagonist methylcaconatine did not prevent the inhibition of LTP induction by Abeta. These studies provide evidence that the Abeta-mediated inhibition of LTP induction involves stimulation of the kinases JNK, Cdk5, and p38 MAPK after the activation of both the Abeta receptor(s) and mGluR5.
在海马切片中,研究了人合成的和天然分泌的细胞源性淀粉样β肽(Aβ)(1-42)对齿状颗粒细胞突触内侧穿通通路中长时程增强(LTP)诱导的作用机制。合成的和细胞源性Aβ在高频刺激(HFS)峰值和HFS后1小时强烈抑制HFS诱导的LTP。细胞源性Aβ在抑制LTP诱导方面比合成Aβ更有效,阈值浓度分别约为1和100-200 nM。通过在这些激酶抑制剂存在的情况下应用Aβ,研究了各种激酶在Aβ介导的LTP诱导抑制中的作用。c-Jun氨基末端激酶(JNK)抑制剂JNKI可防止合成的和细胞源性Aβ对LTP诱导的阻断。JNK抑制剂蒽[1,9-cd]吡唑-6(2H)-酮、细胞周期蛋白依赖性激酶5(Cdk5)抑制剂丁内酯和roscovitine以及p38丝裂原活化蛋白激酶(MAPK)抑制剂4-(4-氟苯基)-2-(4-甲基磺酰基苯基)-5-(4-吡啶基)-1H-咪唑也可防止合成Aβ诱导的LTP阻断,但p42-p44 MAPK抑制剂1,4-二氨基-2,3-二氰基-1,4-双(2-氨基苯硫基)丁二烯则不能。I-II组代谢型谷氨酸受体(mGluR)拮抗剂2S-2-氨基-2-(1S,2S-2-羧基环丙基-1-基)-3-(呫吨-9-基)丙酸和mGluR5拮抗剂甲基-6-(苯乙炔基)吡啶可防止Aβ对LTP诱导的阻断。然而,α7烟碱型乙酰胆碱受体拮抗剂甲基卡可那汀不能防止Aβ对LTP诱导的抑制。这些研究提供了证据,表明Aβ介导的LTP诱导抑制涉及在Aβ受体和mGluR5激活后对JNK、Cdk5和p38 MAPK激酶的刺激。